Seaport Global analyst Angie Storozynski downgrades SJW Gr (NYSE:SJW) from Buy to Neutral.
Lantern Pharma Announces First Patient Dosed In The Phase 1 Study For LP-184 in Advanced Solid Tumors
LP-184 is being studied in a first-in-human Phase 1 clinical trial, having been developed with guidance from Lantern's AI Platform, RADR®, as a potential therapy for a wide range of advanced solid tumors.LP-184 is